Short Answer

Both the model and the market expect Hims & Hers subscribers to be above 2.6 million in Q2 2026, with no compelling evidence of mispricing.

1. Market Behavior & Drivers

This contract, which resolves based on whether Hims & Hers reports over 2.6 million subscribers for Q2 2026, has traded in a tight, sideways channel. The price has been confined to a one-point range, between 93% and 94%, since trading began around July 1. It opened at 94% and currently sits at 93%. This narrow band establishes clear resistance at the 94% level and support at 93%. There have been no significant price spikes or drops driven by external news; the price action reflects a stable, high-conviction expectation ahead of the company's August 10 earnings release.
Total volume is low, with only 377 contracts traded across 40 data points. The light trading suggests a lack of significant new capital entering the market to challenge the existing consensus. The consistently high price, above 90%, indicates strong market sentiment that Hims & Hers will meet the subscriber threshold. The Q1 2026 reported figure was 2.58 million subscribers, so the market is pricing a very high probability of the company adding the net 20,000 subscribers required for a "YES" resolution. The chart shows a market anticipating a specific, incremental growth figure rather than one pricing in significant uncertainty.
  • Since last update (~2d): Model conviction for "Above 2.76 million" increased by +4.0pp, causing the edge to flip.
  • The model similarly became +3.9pp more confident in "Above 2.80 million", again flipping the edge.
  • Overall model confidence increased by +1.0pp, while the headline model probability rose +0.1pp.
  • Subscribers above 2.6 million are highly probable, exceeding current market expectations.
  • Management projects over 100,000 monthly weight loss additions, implying Q2 subscribers exceed 2.88 million.
  • New specialties and marketing efficiencies may further elevate Q2 subscriber counts.

Current Context

Hims & Hers will report Q2 2026 results and subscriber figures soon. The company is scheduled to announce its second quarter 2026 financial results after market close on Monday, August 10, 2026 [1][2][3]. The subscriber count for Q2 2026 will be disclosed in this report. As of the first quarter 2026, Hims & Hers reported approximately 2.58 million subscribers [4][5].
The company provided Q2 guidance and secured new financing. For Q2 2026, Hims & Hers expects revenue between $680 million and $700 million, and Adjusted EBITDA between $35 million and $55 million [4][5]. In early July 2026, the company established a new $400 million receivables facility [6][7].
An FDA committee meeting may impact Hims & Hers' operations. An FDA Pharmacy Compounding Advisory Committee meeting is scheduled for July 23-24, 2026 [8][9]. This committee will review the potential inclusion of seven peptides on the Section 503A Bulks List, a regulatory event that may affect the company's compounding operations [8][9].
Sources (9)
  1. 1Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026barchart.com
  2. 2Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026 | Business | standard-journal.comstandard-journal.com
  3. 3Hims & Hers Q2 2026 earnings call set for Aug. 10 | HIMS Stock Newsstocktitan.net
  4. 4Hims Inc. - Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Resultsinvestors.hims.com
  5. 5Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Resultsbusinesswire.com
  6. 6Hims & Hers sets $400M receivables facility | HIMS 8-K Filingstocktitan.net
  7. 7Hims & Hers Establishes New $400 Million Receivables Facilitytipranks.com
  8. 8HIMS Stock Logs Worst Week In 2 Months — Turns To Peptides Campaign Ahead Of Key FDA Meetingstocktwits.com
  9. 9Hims & Hers Stock Surges as Analysts Lift Price Targets - Hims & Hers Health (NYSE:HIMS) - Benzingabenzinga.com

2. Price Chart

Historical Price (Probability)

Outcome probability
Date

3. Market Data

Contract Snapshot

This Kalshi market resolves 'Yes' if Hims & Hers Health Inc. reports more than 2,760,000 subscribers for Q2 2026, and 'No' if they report 2,760,000 or fewer. The outcome is verified by Fiscal.ai. The market opened on May 21, 2026, closes when the outcome occurs (or by September 2, 2026, 4:00 PM EDT at the latest), with projected payout 30 minutes after closing.

Market Discussion

Hims & Hers reported 2,584,000 subscribers as of March 31, 2026, at the end of Q1 2026 [1]. The company is scheduled to announce its Q2 2026 financial results, including subscriber numbers, on August 10, 2026 [2]. Social media commentary and alternative data sources suggest a potential "reacceleration" in Q2 2026, driven by strong growth in Hers' web traffic and mobile app performance, which could indicate an increase in subscribers [3].

Sources (3)
  1. 1Hims Inc. - Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Resultsinvestors.hims.com
  2. 2Hims & Hers Q2 2026 earnings call set for Aug. 10 | HIMS Stock Newsstocktitan.net
  3. 3🚨 Q2 Revenue Prediction + Data Tracker (Jun 2, 2026)himshouse.substack.com

4. Trader Dashboard

This scorecard was computed Jul 14, 2026 and may not reflect current market conditions.

Trust profile
Event quality9
Poor
Liquidity
9

15 contracts · worst first

Above 2.68 million8
Very thin · low confidence

Light recent trading — size may not fill near the screen price.

Above 2.6 million11
Very thin · low confidence

Light recent trading — size may not fill near the screen price.

Above 2.62 million—
No recent trading to measure

No recent trading to measure

Above 2.64 million—
No recent trading to measure

No recent trading to measure

Above 2.66 million—
No recent trading to measure

No recent trading to measure

Above 2.7 million—
No recent trading to measure

No recent trading to measure

Above 2.72 million—
No recent trading to measure

No recent trading to measure

Above 2.76 million—
No recent trading to measure

No recent trading to measure

Above 2.80 million—
No recent trading to measure

No recent trading to measure

Above 2.84 million—
No recent trading to measure

No recent trading to measure

Above 2.88 million—
No recent trading to measure

No recent trading to measure

Above 2.92 million—
No recent trading to measure

No recent trading to measure

Above 2.96 million—
No recent trading to measure

No recent trading to measure

Above 3.00 million—
No recent trading to measure

No recent trading to measure

Above 3.04 million—
No recent trading to measure

No recent trading to measure

Move quality
—

No reading right now

15 contracts · worst first

Above 2.62 million—
Only 0 candle closes

Only 0 candle closes

Above 2.6 million—
No significant move

No significant move: |move| 0.00 log-odds, 0.0c, vol 0

Above 2.64 million—
Only 0 candle closes

Only 0 candle closes

Above 2.66 million—
Only 0 candle closes

Only 0 candle closes

Above 2.68 million—
No significant move

No significant move: |move| 0.07 log-odds, 1.0c, vol 255

Above 2.7 million—
Only 0 candle closes

Only 0 candle closes

Above 2.72 million—
Only 0 candle closes

Only 0 candle closes

Above 2.76 million—
Only 0 candle closes

Only 0 candle closes

Above 2.80 million—
Only 0 candle closes

Only 0 candle closes

Above 2.84 million—
Only 0 candle closes

Only 0 candle closes

Above 2.88 million—
Only 0 candle closes

Only 0 candle closes

Above 2.92 million—
Only 0 candle closes

Only 0 candle closes

Above 2.96 million—
Only 0 candle closes

Only 0 candle closes

Above 3.00 million—
Only 0 candle closes

Only 0 candle closes

Above 3.04 million—
Only 0 candle closes

Only 0 candle closes

Rule clarity
—Clear

Rules read clean and objective

15 contracts · worst first

Above 2.62 million100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Above 2.6 million100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Above 2.64 million100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Above 2.66 million100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Above 2.68 million100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Above 2.7 million100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Above 2.72 million100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Above 2.76 million100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Above 2.80 million100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Above 2.84 million100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Above 2.88 million100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Above 2.92 million100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Above 2.96 million100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Above 3.00 million100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Above 3.04 million100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear

trader_dashboard_lean_v1.13 · computed Jul 14, 2026

5. What specific drivers for Q2 2026 growth did Hims & Hers management highlight in their Q1 2026 earnings call?

Q1 Marketing % of Revenue36% [1][2][3][4][5]
Projected Monthly Weight Loss SubscribersNorth of 100,000 [6][1][2][3][4][5]
Q2 2026 Revenue Projection$680 million to $700 million [6]
Hims & Hers identified five key drivers for Q2 2026 growth. The company's management highlighted stronger demand in weight loss, continued expansion in newer specialties, improved marketing efficiency, better platform and AI execution, and a broader product assortment facilitating cross-sell as primary drivers for anticipated Q2 2026 subscriber growth [1][2][3][4][5]. These factors are expected to fuel growth by expanding the product mix in weight loss, scaling newer specialty categories, and achieving operating leverage from marketing and platform enhancements [1][2][3][4][5].
Weight loss strategy, featuring branded GLP-1s, is a major driver. A significant contributor to the expected Q2 2026 growth involves a strategic pivot within their weight loss specialty, specifically through the introduction of branded GLP-1 products, including the Wegovy pill and pen [6]. This transition is projected to expand the addressable market and potentially attract "north of 100,000 new subscribers per month" within the weight loss category [6][1][2][3][4][5]. Furthermore, strong demand in newer specialties, such as labs, testosterone, and menopause, is anticipated to scale rapidly, initially domestically and then internationally [1][2][3][4][5].
Improved marketing, advanced AI, and broader offerings support growth. Management emphasized improved marketing efficiency, with marketing as a percentage of revenue improving by 3 points to 36% in Q1, attributed to better retention, increased cross-sell, and more acquisitions via lower-cost channels [1][2][3][4][5]. Robust technology and AI are expected to enhance platform personalization, leverage consumer insights, improve care quality, deepen engagement, and increase user tenure [1][2][3][4][5]. A wider assortment on the platform is also noted for increasing traffic and demand, creating additional opportunities for cross-selling. For Q2 2026, Hims & Hers projects revenue between $680 million and $700 million, reflecting an anticipated 25% to 28% year-over-year increase [6].
Sources (6)
  1. 1HIMS_Q12026, Page: 4Octagon Agentoctagonai.co
  2. 2HIMS_Q12026, Page: 10Octagon Agentoctagonai.co
  3. 3HIMS_Q12026, Page: 5Octagon Agentoctagonai.co
  4. 4HIMS_Q12026, Page: 9Octagon Agentoctagonai.co
  5. 5HIMS_Q12026, Page: 8Octagon Agentoctagonai.co
  6. 6Hims & Hers swings to a loss in Q1 amid shift in GLP-1 strategyfiercehealthcare.com

6. How might the FDA's Pharmacy Compounding Advisory Committee meeting in July 2026 impact Hims & Hers' subscriber growth?

FDA Committee Meeting DateJuly 23-24, 2026 [1][2][3]
Hims & Hers Q1 2026 Subscribers2.584 million [4][5][6][7][8][9]
Weight-loss Revenue ShareAround one-third of total revenue [4][5][6][7][8][9]
The FDA's Pharmacy Compounding Advisory Committee meeting in July 2026 is critical for Hims & Hers’ subscriber growth. Scheduled for July 23-24, 2026, the committee will evaluate including bulk drug substances like BPC-157, KPV, TB-500, and MOTs-C on the 503A Bulks List [1][2][3]. The meeting's uncertain outcome could significantly influence Hims & Hers’ trajectory; a positive or neutral stance could support continued subscriber expansion by protecting or enhancing its weight-loss and peptide-related product lines. Conversely, a restrictive decision could hinder growth by limiting a crucial channel for customer acquisition [4][5][6][7][8][9].
Increasing regulatory scrutiny on compounding has impacted Hims & Hers’ strategic direction. This meeting is part of a broader trend that previously led to significant restrictions on compounded GLP-1 telehealth services, prompting Hims & Hers to shift its strategy towards branded GLP-1 products [10][11][12][13][14]. In Q1 2026, Hims & Hers reported 2.584 million subscribers, with its weight-loss sector contributing approximately one-third of its total revenue and serving as a major driver of growth [4][5][6][7][8][9]. While analysts indicate the market anticipates a favorable outcome for peptides, suggesting a positive committee signal could boost investor confidence and support subscriber acquisition, reports of FDA staff recommending against allowing compounding pharmacies to produce seven peptides imply a negative recommendation could constrain Hims & Hers’ peptide offerings and decelerate its growth momentum [4][5][6][7][8][9].
The meeting's effects will influence future growth, not immediate results. Despite its potential long-term implications, the meeting's impact is more likely to affect Hims & Hers’ future growth rate and investor sentiment rather than immediately altering reported Q2 2026 subscriber figures. As of July 14, 2026, Hims & Hers had not yet released its Q2 2026 results, with the Q2 earnings call scheduled for August 4, 2026, after market close [4][5][6][7][8][9].
Sources (14)
  1. 1July 23-24, 2026: Meeting of the Pharmacy Compounding...fda.gov
  2. 2Pharmacy Compounding Advisory Committee; Notice...federalregister.gov
  3. 3Federal Register, Volume 91 Issue 73 (Thursday, April 16, 2026)govinfo.gov
  4. 4seekingalpha.comOctagon Agent
  5. 5www.zacks.comOctagon Agentzacks.com
  6. 6www.fool.comOctagon Agentfool.com
  7. 7www.marketbeat.comOctagon Agentmarketbeat.com
  8. 8seekingalpha.comOctagon Agent
  9. 9www.etftrends.comOctagon Agentetftrends.com
  10. 10Hims & Hers Revenue Cliff: FDA Ends GLP-1 Compounding Lifelineainvest.com
  11. 11503A and the PCAC: how compounding restrictions closed the legal GLP-1 marketvialaudit.com
  12. 12Hims & Hers Health, Inc. Reports First Quarter 2026...investors.hims.com
  13. 13Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Resultsbusinesswire.com
  14. 14Hims Hers Health, Inc. (HIMS) 8-K Earnings Release - May 2026last10k.com

7. How has Hims & Hers' actual subscriber growth historically compared to its quarterly financial guidance?

Subscribers by Q1 2026Nearly 2.6 million [1][2][3][4][5][6][7][8]
Guidance FocusPrimarily financial metrics like revenue and EBITDA [5][9][10][11][12][13][14][15]
Subscriber Guidance for ComparisonNot indicated in available evidence for historical comparison [10][11][12][13][14][15]
Hims & Hers consistently demonstrated strong subscriber growth, meeting market expectations. The company has shown robust and consistent subscriber expansion, frequently meeting or exceeding market expectations. Hims & Hers reached approximately 2.6 million subscribers by the first quarter of 2026 [1][2][3][4][5][6][7][8].
Hims & Hers' forward-looking guidance prioritizes financial metrics. However, the company's forward-looking guidance primarily focuses on financial metrics, such as revenue and EBITDA, rather than providing specific subscriber-count guidance [5][9][10][11][12][13][14][15]. For Q2 2026 and Q2 2025, the available information does not report actual subscriber counts or specific subscriber growth guidance ranges [10][11][12][13][14][15].
Direct comparison of subscriber growth to guidance is not possible. Consequently, based on the provided research, there is insufficient information to directly compare Hims & Hers' actual subscriber growth to its quarterly subscriber-count guidance, as such specific guidance is not indicated in the available evidence [10][11][12][13][14][15].
Sources (15)
  1. 1Hims & Hers Health, Inc. Reports First Quarter 2026...investors.hims.com
  2. 2Hims & Hers Health, Inc. Reports Fourth Quarter and Full...investors.hims.com
  3. 3Hims Hers Health, Inc. (HIMS) 10-Q Quarterly Report May 2026last10k.com
  4. 4Hims Inc. - Financials - Quarterly resultsinvestors.hims.com
  5. 5Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Resultsbusinesswire.com
  6. 6Hims & Hers Health (HIMS) Operating Metrics & Breakdownsstockanalysis.com
  7. 7finalq22025shareholderlesec.gov
  8. 8Hims Hers Health, Inc. (HIMS) 8-K Earnings Release - Nov 2025last10k.com
  9. 9Will Hims & Hers Health Beat Quarterly Earnings?lines.com
  10. 10seekingalpha.comOctagon Agent
  11. 11www.zacks.comOctagon Agentzacks.com
  12. 12www.fool.comOctagon Agentfool.com
  13. 13www.marketbeat.comOctagon Agentmarketbeat.com
  14. 14seekingalpha.comOctagon Agent
  15. 15www.etftrends.comOctagon Agentetftrends.com

8. What has been the quarter-over-quarter subscriber growth rate for Hims & Hers over the last eight quarters?

Q1 2026 Subscribersnearly 2.6 million [1][2]
Q4 2025 Subscribers~2.51 million [3]
Q3 2025 Subscribers2.47 million [3]
Hims & Hers quarter-over-quarter subscriber growth rates are not explicitly detailed. The provided research does not contain the specific quarter-over-quarter subscriber growth rate for Hims & Hers over the last eight quarters. Information necessary to precisely calculate these rates for several quarters is unavailable [1][2]. While the subscriber count for Q1 2026 showed a 9% year-over-year increase compared to Q1 2025, the explicit quarter-over-quarter growth rates are not provided in the source materials [1][2].
However, subscriber counts for recent quarters are publicly available. Hims & Hers reported nearly 2.6 million subscribers as of Q1 2026 [1][2]. This followed approximately 2.51 million subscribers in Q4 2025 [3], 2.47 million in Q3 2025 [3], over 2.4 million in Q2 2025 [4], and 2.366 million in Q1 2025 [5].
Sources (5)
  1. 1Hims & Hers Health, Inc. Reports First Quarter 2026...investors.hims.com
  2. 2Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Resultsbusinesswire.com
  3. 3Hims Hers Health, Inc. (HIMS) 8-K Earnings Release - Nov 2025last10k.com
  4. 4Hims & Hers Health, Inc. Reports Second Quarter 2025...investors.hims.com
  5. 5Hims & Hers Health (HIMS) Operating Metrics & Breakdownsstockanalysis.com

9. What is the consensus among Wall Street analysts for Hims & Hers' Q2 2026 subscriber count?

Q1 2026 Subscribers2.584 million [1][2][3]
Kalshi prediction market Q2 threshold2.76 million [4][5]
Coinbase prediction market Q2 threshold2.84 million [6][7][8][9][10][11]
Wall Street analysts have not published a consensus subscriber estimate for Hims & Hers’ Q2 2026. While analysts have issued revenue and EPS estimates for Hims & Hers’ Q2 2026 results, a confirmed consensus figure specifically for subscriber count is not available [6][7][8][9][10][11].
Hims & Hers reported 2.584 million subscribers at the close of Q1 2026. Following this, analyst optimism for Hims & Hers increased in July 2026, with firms raising price targets due to strong Q2 subscription retention and effective core telehealth execution [12]. However, these positive adjustments did not encompass a Wall Street consensus subscriber estimate [6][7][8][9][10][11].
Prediction markets indicate subscriber expectations around or above 2.76 million for Q2 2026. Kalshi, a prediction market platform, established a threshold of 2.76 million for its "Hims & Hers subscribers in Q2" market, suggesting market expectations centered at or above this number [4][5]. Furthermore, a 2.84 million threshold in a Coinbase prediction market was identified as another public data point related to subscriber expectations, although this is not a Wall Street consensus [6][7][8][9][10][11].
Sources (12)
  1. 1Hims Inc. - Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Resultsinvestors.hims.com
  2. 2Hims & Hers Q1 2026 Earnings Review -finsee.ai
  3. 3Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Resultsbusinesswire.com
  4. 4Hims & Hers subscribers in Q2 Odds & Predictions 2026kalshi.com
  5. 5Hims & Hers subscribers in Q2 | Prediction Marketscoinbase.com
  6. 6seekingalpha.comOctagon Agent
  7. 7www.zacks.comOctagon Agentzacks.com
  8. 8www.fool.comOctagon Agentfool.com
  9. 9www.marketbeat.comOctagon Agentmarketbeat.com
  10. 10seekingalpha.comOctagon Agent
  11. 11www.etftrends.comOctagon Agentetftrends.com
  12. 12Hims & Hers Health Forecast +8%: Surge on Upgradesstocknewsroom.com

10. What Could Change the Odds

Key Catalysts

Hims & Hers is scheduled to report its Q2 2026 financial results on August 10, 2026 [1][2]. Q2 subscriber metrics will be released on August 10 [3][4][5]. In Q1 2026, Hims & Hers reached approximately 2.58 million subscribers [3][4][5]. Full-year 2026 financial guidance includes revenue of $2.8 billion to $3.0 billion and Adjusted EBITDA of $275 million to $350 million [4][6].
Key catalysts include the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23–24, 2026, to review peptides [6]. The integration of the Eucalyptus acquisition, closed in early June 2026, also represents a factor [6].
Bullish sentiment is driven by potential expansion into a $20 billion addressable market for non-GLP-1 peptides and accelerating subscriber growth in the second quarter [7][6]. Bearish risks include potential FDA restrictions on compounded peptides, regulatory headwinds, and potential margin pressure from GLP-1 transition investments [7][6].

Key Dates & Catalysts

  • Expiration: September 02, 2026
  • Closes: September 02, 2026
Sources (7)
  1. 1Hims & Hers Q2 2026 earnings call set for Aug. 10 | HIMS Stock Newsstocktitan.net
  2. 2Hims & Hers Health (HIMS) Earnings Date and Reports 2026marketbeat.com
  3. 3Hims Inc. - Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Resultsinvestors.hims.com
  4. 4Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Resultsbusinesswire.com
  5. 5Hims Hers Health, Inc. (HIMS) 8-K Earnings Release - May 2026last10k.com
  6. 6Hims & Hers Stock Closes Eucalyptus Deal With a $20 Billion Peptide Bet on Deck. Here’s What to Expect | TIKR.comtikr.com
  7. 7Hims & Hers Stock Surges as Analysts Lift Price Targets - Hims & Hers Health (NYSE:HIMS) - Benzingabenzinga.com

12. Historical Resolutions

Historical Resolutions: 9 markets in this series

Outcomes: 4 resolved YES, 5 resolved NO

Recent resolutions:

  • KXHIMS-26MAYSUBS-2800000.0: NO (May 11, 2026)
  • KXHIMS-26MAYSUBS-2750000.0: NO (May 11, 2026)
  • KXHIMS-26MAYSUBS-2700000.0: NO (May 11, 2026)
  • KXHIMS-26MAYSUBS-2650000.0: NO (May 11, 2026)
  • KXHIMS-26MAYSUBS-2600000.0: NO (May 11, 2026)